IBRX
Price:
$5.1
Market Cap:
$3.55B
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amy...[Read more]
Industry
Biotechnology
IPO Date
2015-07-28
Stock Exchange
NASDAQ
Ticker
IBRX
According to ImmunityBio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.67. This represents a change of -12.20% compared to the average of -6.46 of the last 4 quarters.
The mean historical PE Ratio of ImmunityBio, Inc. over the last ten years is -182.20. The current -5.67 PE Ratio has changed 211.20% with respect to the historical average. Over the past ten years (40 quarters), IBRX's PE Ratio was at its highest in in the December 2014 quarter at 0. The PE Ratio was at its lowest in in the June 2015 quarter at -31.52.
Average
-182.20
Median
-5.05
Minimum
-1760.30
Maximum
-0.95
Discovering the peaks and valleys of ImmunityBio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 12.95%
Maximum Annual PE Ratio = -0.95
Minimum Annual Increase = -99.70%
Minimum Annual PE Ratio = -1760.30
Year | PE Ratio | Change |
---|---|---|
2023 | -4.38 | -9.88% |
2022 | -4.86 | -28.18% |
2021 | -6.76 | -70.31% |
2020 | -22.78 | 151.26% |
2019 | -9.07 | 850.55% |
2018 | -0.95 | -74.58% |
2017 | -3.75 | -3.32% |
2016 | -3.88 | -25.82% |
2015 | -5.23 | -99.70% |
2014 | -1760.30 | 12.95% |
The current PE Ratio of ImmunityBio, Inc. (IBRX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.33
5-year avg
-9.57
10-year avg
-182.20
ImmunityBio, Inc.’s PE Ratio is less than BioLineRx Ltd. (0), less than Ardelyx, Inc. (-0.74), greater than Lexicon Pharmaceuticals, Inc. (-17.26), less than Seres Therapeutics, Inc. (-1.45), less than eFFECTOR Therapeutics, Inc. (-4.61), less than Protalix BioTherapeutics, Inc. (-0.00), greater than PDS Biotechnology Corporation (-12.94), less than aTyr Pharma, Inc. (-1.90), less than Elevation Oncology, Inc. (-2.33), less than CureVac N.V. (-0.85), less than Reata Pharmaceuticals, Inc. (5.18), greater than Krystal Biotech, Inc. (-20.07), less than Vir Biotechnology, Inc. (104.40), less than Propanc Biopharma, Inc. (-1.82), less than Viking Therapeutics, Inc. (-0.09), greater than TG Therapeutics, Inc. (-58.83), greater than X4 Pharmaceuticals, Inc. (-354.27), less than Madrigal Pharmaceuticals, Inc. (-4.05), greater than null (-14.57),
Company | PE Ratio | Market cap |
---|---|---|
0 | $38.31M | |
-0.74 | $1.26B | |
-17.26 | $312.11M | |
-1.45 | $131.23M | |
-4.61 | $941.00 | |
-0.00 | $124.44M | |
-12.94 | $78.19M | |
-1.90 | $131.12M | |
-2.33 | $35.67M | |
-0.85 | $596.65M | |
5.18 | $6.57B | |
-20.07 | $5.48B | |
104.40 | $980.57M | |
-1.82 | $236.97K | |
-0.09 | $5.86B | |
-58.83 | $5.46B | |
-354.27 | $57.64M | |
-4.05 | $7.58B | |
-14.57 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunityBio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmunityBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ImmunityBio, Inc.'s PE Ratio?
How is the PE Ratio calculated for ImmunityBio, Inc. (IBRX)?
What is the highest PE Ratio for ImmunityBio, Inc. (IBRX)?
What is the 3-year average PE Ratio for ImmunityBio, Inc. (IBRX)?
What is the 5-year average PE Ratio for ImmunityBio, Inc. (IBRX)?
How does the current PE Ratio for ImmunityBio, Inc. (IBRX) compare to its historical average?